Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totaling 300 shares, a drop of 91.4% from the April 15th total of 3,506 shares. Based on an average trading volume of 223,293 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are short sold.
Bioxytran Trading Up 0.8%
Shares of Bioxytran stock opened at $0.04 on Wednesday. Bioxytran has a twelve month low of $0.03 and a twelve month high of $0.17. The stock has a market capitalization of $4.07 million, a P/E ratio of -1.80 and a beta of 1.95. The business’s fifty day moving average price is $0.04 and its 200 day moving average price is $0.06.
Bioxytran Company Profile
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.
Recommended Stories
- Five stocks we like better than Bioxytran
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
